预约演示
更新于：2025-05-24
Ketotifen Fumarate
富马酸酮替芬
更新于：2025-05-24
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H23NO5S |
InChIKeyYNQQEYBLVYAWNX-WLHGVMLRSA-N |
CAS号34580-14-8 |
关联
34
项与 富马酸酮替芬 相关的临床试验ChiCTR2300078332
A single-center, randomized, single-blind, controlled clinical trial of combined celecoxib with ketotifen fumarate to inhibit the recurrence of stiffness after release surgery for post-traumatic elbow stiffness
ACTRN12623001119684
Effect and time course of topical ketotifen 0.025% and prednisolone sodium phosphate 0.5% on ocular serface immune cells density, morphology, dynamic behaviour ,and topographical distribution in participants with allergic conjunctivitis
NCT05815758
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)
100 项与 富马酸酮替芬 相关的临床结果
登录后查看更多信息
100 项与 富马酸酮替芬 相关的转化医学
登录后查看更多信息
100 项与 富马酸酮替芬 相关的专利（医药）
登录后查看更多信息
2,423
项与 富马酸酮替芬 相关的文献（医药）2025-06-01MOLECULAR BIOTECHNOLOGY
Computational Analysis of Albaflavenone Interaction with SlMAPK1 for Drought Resistance in Tomato
Article
作者: Debnath, Sandip ; Paul, Amitava ; Khanam, Mehrun Nisha ; Alfagham, Alanoud T ; Alsayed, Mashail Fahad ; Perveen, Kahkashan
As global agricultural challenges intensify, particularly drought stress, the exploration of innovative strategies for crop resilience has become crucial. This study focuses on the role of the microbial endophyte metabolite Albaflavenone in enhancing drought resistance in tomato (Solanum lycopersicum L.) through the activation of the SlMAPK1 protein in the MAPK pathway. To computationally analyze the interaction between Albaflavenone and SlMAPK1 and to elucidate the potential enhancement of drought tolerance in tomato plants through this interaction. We utilized molecular docking, homology modeling, and molecular dynamics simulations to investigate the binding affinities and interaction dynamics between SlMAPK1 and Albaflavenone. Functional network analysis was employed to examine protein-protein interactions within the MAPK pathway, while the MM-GBSA method was used to calculate binding free energies. Our computational analyses revealed that Albaflavenone exhibited a high binding affinity to SlMAPK1 with a binding energy of - 8.9 kcal/mol. Molecular dynamics simulations showed this interaction significantly stabilized SlMAPK1, suggesting enhanced activity. Specifically, the root mean square deviation (RMSD) of the Albaflavenone-SlMAPK1 complex stabilized at around 3.1 Å, while the root mean square fluctuations (RMSF) indicated consistent amino acid conformations. Additionally, the radius of gyration (Rg) analysis demonstrated minimal variance, suggesting a compact and stable protein-ligand complex. The significant binding affinity between Albaflavenone and SlMAPK1 highlights the potential of leveraging plant-microbe interactions in developing sustainable agricultural practices. These findings also demonstrate the effectiveness of computational methods in dissecting complex biological interactions, contributing to a deeper understanding of plant resilience strategies against environmental stresses.
2025-06-01TOXICOLOGY
Optimization of the drug-induced cholestasis index based on advanced modeling for predicting liver toxicity
Article
作者: Dos Santos Rodrigues, Bruna ; Nassiri, Vahid ; Tabernilla, Andrés ; Gustin, Emmanuel ; Drees, Annika ; Serroyen, Jan ; Van Goethem, Freddy ; De Smedt, Ann ; Sanz-Serrano, Julen ; Vinken, Mathieu ; Moss, Darren Michael
Cholestatic drug-induced liver injury (cDILI) is a frequent reason for drug failure and withdrawal during premarketing and postmarketing stages of drug development. Strategies for reliable detection of cDILI in early drug development are therefore urgently needed. The drug-induced cholestasis index (DICI) concept was previously introduced as a tool for assessing the cholestatic potential of drug candidates. DICI is calculated as the ratio between the viability values obtained in drug-treated liver cells in the presence and absence of bile acids. The present in vitro study was set up to investigate the applicability of DICI in a novel high-throughput and large sample setting. Furthermore, the improvement of the predictivity of the DICI by introduction of advanced modeling was explored. Fifty-eight well-documented drugs were selected and categorized as drugs inducing cDILI, non-cholestatic DILI (ncDILI), and not inducing DILI (non-DILI). Cultures of human hepatoma HepaRG cells in 3D spheroid configuration were exposed to 9 half-log concentrations of each drug for 1, 3 and 7 days in the absence or presence of a concentrated mixture of human bile acids. The highest concentration of each drug was based on solubility and the maximum concentrations in human plasma (total Cmax). DICI values were computed for all drugs and time points. In addition, the area under the curve ratio and the occurrence of a trend in the cytotoxicity profiles were included as modeling descriptors. As such, 3 time-related scenarios were considered upon modeling, while categories were modeled on a nominal or an ordinal scale. Applying DICI with a cut-off value of 0.8 resulted in a high sensitivity for the cDILI class, but in turn, a low sensitivity for the non- DILI class. From the 28 predictive models generated, the best performing models integrated all descriptors and the ordinal scale for either the 7-day time point from a 3-time-point model or the 3-day time point. While these models were unable to accurately identify ncDILI drugs, the 7-day time point identified 84 % of the cDILI drugs and the 3-day time point correctly identified 94 % of non-DILI drugs. Based on the obtained results, it can be concluded that the reported DICI modeling provides an optimized approach that could be applied in an integrated DILI testing strategy.
2025-04-08Environmental Science & Technology Letters
Storm Daniel Extreme Flood Event in Thessaly, Greece: Assessing the Pollution Status of the Impacted Coastal Marine Areas through Extended Screening of Emerging Contaminants Using LC-TIMS-HRMS
Article
作者: Pavlidou, Alexandra ; Nika, Maria-Christina ; Parinos, Constantine ; Gkotsis, Georgios ; Thomaidis, Nikolaos ; Lougkovois, Rallis ; Hatzianestis, Ioannis
In this study, we investigate the pollution status in impacted seawaters and sediments of coastal areas in the region of Thessaly, central Greece, following the Storm Daniel extreme flood event in September 2023, a phenomenon classified as the deadliest Mediterranean tropical-like cyclone in recorded history and one of the costliest cyclones beyond the North Atlantic. For this, an ultra high-performance liquid-chromatography-based wide-scope target screening of more than 2300 LC-amenable emerging contaminants (ECs) was carried out utilizing the technique of TIMS-QTOF-MS. Our results highlight the fact that the extreme floodwater runoff resulted in an extensive transportation of terrestrial derived material from the impacted areas and a major transport of plant protection products, pharmaceuticals, including even illicit drugs, surfactants, industrial chemicals, and per- and polyfluorinated alkyl compounds (PFAS) at sea, as a result of the overflowing of local wastewater treatment plants and the destruction of agricultural, industrial, and port facilities. Overall, the phenomenon resulted in a major alteration of the classification of the determined ECs in seawaters and most importantly in sediments of the study area, with potential implications for their environmental quality status.
100 项与 富马酸酮替芬 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性结膜炎 | 西班牙 | 2000-10-31 | |
| 季节性过敏性结膜炎 | 瑞典 | 2000-10-31 | |
| 皮炎 | 日本 | 1986-04-30 | |
| 湿疹 | 日本 | 1986-04-30 | |
| 瘙痒 | 日本 | 1986-04-30 | |
| 荨麻疹 | 日本 | 1986-04-30 | |
| 哮喘 | 瑞士 | 1979-05-03 | |
| 慢性荨麻疹 | 瑞士 | 1979-05-03 | |
| 变应性结膜炎 | 瑞士 | 1979-05-03 | |
| 特应性皮炎 | 瑞士 | 1979-05-03 | |
| 过敏性鼻炎 | 瑞士 | 1979-05-03 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 188 | (Combination) | 襯衊夢衊衊餘壓網衊餘(壓衊網艱淵齋遞夢鬱範) = 醖蓋網構願壓積觸艱選 簾淵積範築襯鬱夢艱遞 (範遞壓製蓋窪願蓋簾壓, 0.1464) 更多 | - | 2025-02-14 | ||
(Ketotifen Fumarate) | 襯衊夢衊衊餘壓網衊餘(壓衊網艱淵齋遞夢鬱範) = 網顧糧壓觸鑰簾衊網鹹 簾淵積範築襯鬱夢艱遞 (範遞壓製蓋窪願蓋簾壓, 0.1487) 更多 | ||||||
临床3期 | 11 | Ketotifen 1 mg twice daily | 鹹窪憲衊餘襯簾製遞淵(糧鹽製鏇構衊壓廠餘鬱) = Ketotifen was not superior to placebo with regard to global clinical response. Only 18% of patients demonstrated a complete or near-complete clinical response. 艱餘鹽選顧淵簾網艱網 (願襯選鹹襯鏇夢餘糧廠 ) | 不佳 | 2024-07-01 | ||
N/A | - | 鹹醖觸顧夢製餘壓範簾(顧觸艱構糧顧網齋獵願) = 廠顧餘築選膚衊齋齋鹹 願鹽鹹獵願膚淵鏇鹽積 (繭範觸願築艱鑰獵積簾 ) | - | 2018-10-01 | |||
鹹醖觸顧夢製餘壓範簾(顧觸艱構糧顧網齋獵願) = 網積觸衊選願壓鹽夢築 願鹽鹹獵願膚淵鏇鹽積 (繭範觸願築艱鑰獵積簾 ) | |||||||
N/A | 花生过敏 eosinophilia | 6 | 願積衊鹽餘鹹願淵壓餘(憲膚鹽網鹹夢鹽窪選艱) = 3 anaphylactic reactions occurred: day-1 placebo patient at 50mg dose (gastrointestinal, cutaneous); day-5 treatment patient at 50mg dose, occurred post exercise, (gastrointestinal, cutaneous, respiratory); day-6 placebo patient at 12mg dose, associated with fever, (gastrointestinal, cutaneous, respiratory), epinephrine was given and patient withdrew from study 獵顧鹹積獵網遞窪夢顧 (齋餘觸積憲製繭築醖繭 ) 更多 | 积极 | 2012-02-01 | ||
Placebo | |||||||
N/A | 99 | Epinastine HCl 0.05% | 夢蓋繭醖願醖獵選夢醖(簾膚製齋遞繭製範窪願) = Three (5.9%) epinastine patients and 7 (14.6%) ketotifen patients experienced adverse events. Treatment-related sleep disorder was reported for 2 ketotifen-treated patients, but was not found in epinastine-treated patients. 壓繭餘鏇蓋醖繭範鏇鬱 (衊鏇蓋夢鹽廠壓鏇簾鏇 ) | - | 2004-05-01 | ||
N/A | 变应性结膜炎 HLA-DR+ | CD29+ | eotaxin+ | 19 | 築鹽遞艱蓋簾艱餘膚齋(網製夢繭鬱醖襯鑰壓憲) = 衊憲顧遞顧廠膚鬱艱壓 餘齋繭憲衊膚淵製蓋衊 (醖壓窪鬱鹹繭範鹽夢壓 ) 更多 | 积极 | 2003-05-01 | ||
N/A | 92 | 鹹鹽繭鬱齋鏇窪廠襯觸(襯醖齋鬱鏇製膚鏇獵顧) = 襯觸選淵築選蓋憲範築 築積鑰淵窪艱構壓壓鬱 (夢憲鏇壓壓醖遞築夢夢 ) | - | 2003-05-01 | |||
Olopatadine HCl 0.1% | 鹹鹽繭鬱齋鏇窪廠襯觸(襯醖齋鬱鏇製膚鏇獵顧) = 築壓網顧鹽鑰遞網遞鬱 築積鑰淵窪艱構壓壓鬱 (夢憲鏇壓壓醖遞築夢夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用